{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:51:36Z","timestamp":1790736696044,"version":"4.1.0"},"reference-count":37,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,6,1]]},"abstract":"<jats:p>OBJECTIVE. Noonan syndrome is a clinically homogeneous but genetically heterogeneous condition. Type 1 Noonan syndrome is defined by the presence of a mutation in the PTPN11 gene, which is found in \u223c40% of the cases. Phenotype descriptions and cardiac defects from cohorts with Noonan syndrome were delineated in the \u201cpregenomic era.\u201d We report the heart defects and links to gene dysfunction in cardiac development in a large cohort of patients with type 1 Noonan syndrome.<\/jats:p>\n                  <jats:p>METHODS. This was a retrospective, multicenter study based on clinical history, pictures, and medical and cardiologic workup over time. Data were collected by referral geneticists. Mutation screening was performed by direct sequencing of exons 2, 3, 4, 7, 8, 12, and 13 and their intron-exon boundaries, which harbor 98% of identified mutations the PTPN11 gene.<\/jats:p>\n                  <jats:p>RESULTS. A PTPN11 gene mutation was identified in 104 (38.25%) of 274 patients with Noonan syndrome. Heart defect was present in 85%. The most prevalent congenital heart defects were pulmonary valve stenosis (60%), atrial septal defect, ostium secundum type (25%), and stenosis of the peripheral pulmonary arteries (in at least 15%). Pulmonary valve stenosis and atrial septal defect, ostium secundum type, were significantly associated with the identification of a mutation in the PTPN11 gene. Ventricular septal defect and most left-sided heart defects showed a trend toward overrepresentation in the group without a mutation.<\/jats:p>\n                  <jats:p>CONCLUSION. We compared our data with previous series and integrated the comprehension of molecular PTPN11 gene dysfunction in heart development.<\/jats:p>","DOI":"10.1542\/peds.2006-0211","type":"journal-article","created":{"date-parts":[[2007,5,22]],"date-time":"2007-05-22T12:59:32Z","timestamp":1179838772000},"page":"e1325-e1331","source":"Crossref","is-referenced-by-count":96,"title":["The Spectrum of Cardiac Anomalies in Noonan Syndrome as a Result of Mutations in the\n                    <i>PTPN11<\/i>\n                    Gene"],"prefix":"10.1542","volume":"119","author":[{"given":"Yves","family":"Sznajer","sequence":"first","affiliation":[{"name":"Department of Medical Genetics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Keren","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarisse","family":"Baumann","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Pereira","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Alberti","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Unit"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Elion","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He\u0301le\u0300ne","family":"Cave\u0301","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Verloes","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics"},{"name":"Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale INSERM U676, AP-HP Robert Debre\u0301 University Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2007,6,1]]},"reference":[{"key":"2021120902021098000_R1","doi-asserted-by":"crossref","unstructured":"Nora JJ, Nora AH, Sinha AK, Spangler RD, Lubs HA. The Ullrich-Noonan syndrome (Turner phenotype). Am J Dis Child.\u20081974;127:48\u201355","DOI":"10.1001\/archpedi.1974.02110200050007"},{"key":"2021120902021098000_R2","doi-asserted-by":"crossref","unstructured":"Marino B, Digilio MC, Toscano A, Giannotti A, Dallapiccola B. Congenital heart diseases in children with Noonan syndrome: an expanded cardiac spectrum with high prevalence of atrioventricular canal. J Pediatr.\u20081999;135:703\u2013706","DOI":"10.1016\/S0022-3476(99)70088-0"},{"key":"2021120902021098000_R3","doi-asserted-by":"crossref","unstructured":"Schubbert S, Zenker M, Rowe SL, et al. Germline KRAS mutations cause Noonan syndrome. Nat Genet.\u20082006;38:331\u2013336","DOI":"10.1038\/ng1748"},{"key":"2021120902021098000_R4","doi-asserted-by":"crossref","unstructured":"Roberts AE, Araki T, Swanson KD, et al. Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet.\u20082007;39:70\u201374","DOI":"10.1038\/ng1926"},{"key":"2021120902021098000_R5","doi-asserted-by":"crossref","unstructured":"Tartaglia M, Pennacchio LA, Zhao C, et al. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet.\u20082007;39:75\u201379","DOI":"10.1038\/ng1939"},{"key":"2021120902021098000_R6","doi-asserted-by":"crossref","unstructured":"Tartaglia M, Kalidas K, Shaw A, et al. PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet.\u20082002;70:1555\u20131563","DOI":"10.1086\/340847"},{"key":"2021120902021098000_R7","doi-asserted-by":"crossref","unstructured":"Sarkozy A, Conti E, Seripa D, et al. Correlation between PTPN11 gene mutations and congenital heart defects in Noonan and LEOPARD syndromes. J Med Genet.\u20082003;40:704\u2013708","DOI":"10.1136\/jmg.40.9.704"},{"key":"2021120902021098000_R8","doi-asserted-by":"crossref","unstructured":"Musante L, Kehl HG, Majewski F, et al. Spectrum of mutations in PTPN11 and genotype-phenotype correlation in 96 patients with Noonan syndrome and five patients with cardio-facio-cutaneous syndrome. Eur J Hum Genet.\u20082003;11:201\u2013206","DOI":"10.1038\/sj.ejhg.5200935"},{"key":"2021120902021098000_R9","doi-asserted-by":"crossref","unstructured":"Zenker M, Buheitel G, Rauch R, et al. Genotype-phenotype correlations in Noonan syndrome. J Pediatr.\u20082004;144:368\u2013374","DOI":"10.1016\/j.jpeds.2003.11.032"},{"key":"2021120902021098000_R10","doi-asserted-by":"crossref","unstructured":"Yoshida R, Hasegawa T, Hasegawa Y, et al. Protein-tyrosine phosphatase, nonreceptor type 11 mutation analysis and clinical assessment in 45 patients with Noonan syndrome. J Clin Endocrinol Metab.\u20082004;89:3359\u20133364","DOI":"10.1210\/jc.2003-032091"},{"key":"2021120902021098000_R11","doi-asserted-by":"crossref","unstructured":"Jongmans M, Sistermans EA, Rikken A, et al. Genotypic and phenotypic characterization of Noonan syndrome: new data and review of the literature. Am J Med Genet A.\u20082005;134:165\u2013170","DOI":"10.1002\/ajmg.a.30598"},{"key":"2021120902021098000_R12","doi-asserted-by":"crossref","unstructured":"Keren B, Hadchouel A, Saba S, et al. PTPN11 mutations in patients with LEOPARD syndrome: a French multicentric experience. J Med Genet.\u20082004;41:e117","DOI":"10.1136\/jmg.2004.021451"},{"key":"2021120902021098000_R13","doi-asserted-by":"crossref","unstructured":"Fragale A, Tartaglia M, Wu J, Gelb BD. Noonan syndrome-associated SHP2\/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2\/MAPK1 activation. Hum Mutat.\u20082004;23:267\u2013277","DOI":"10.1002\/humu.20005"},{"key":"2021120902021098000_R14","doi-asserted-by":"crossref","unstructured":"Lee JS, Tartaglia M, Gelb BD, et al. Phenotypic and genotypic characterisation of Noonan-like\/multiple giant cell lesion syndrome. J Med Genet.\u20082005;42:e11","DOI":"10.1136\/jmg.2004.024091"},{"key":"2021120902021098000_R15","doi-asserted-by":"crossref","unstructured":"Tartaglia M, Gelb BD. Noonan syndrome and related disorders: genetics and pathogenesis. Annu Rev Genomics Hum Genet.\u20082005;6:45\u201368","DOI":"10.1146\/annurev.genom.6.080604.162305"},{"key":"2021120902021098000_R16","doi-asserted-by":"crossref","unstructured":"Tartaglia M, Martinelli S, Stella L, et al. Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am J Hum Genet.\u20082006;78:279\u2013290","DOI":"10.1086\/499925"},{"key":"2021120902021098000_R17","doi-asserted-by":"crossref","unstructured":"Niihori T, Aoki Y, Ohashi H, et al. Functional analysis of PTPN11\/SHP-2 mutants identified in Noonan syndrome and childhood leukemia. J Hum Genet.\u20082005;50:192\u2013202","DOI":"10.1007\/s10038-005-0239-7"},{"key":"2021120902021098000_R18","doi-asserted-by":"crossref","unstructured":"Keilhack H, David FS, McGregor M, Cantley LC, Neel BG. Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. J Biol Chem.\u20082005;280:30984\u201330993","DOI":"10.1074\/jbc.M504699200"},{"key":"2021120902021098000_R19","doi-asserted-by":"crossref","unstructured":"Hanna N, Montagner A, Lee WH, et al. Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: consequences for PI3K binding on Gab1. FEBS Lett.\u20082006;580:2477\u20132482","DOI":"10.1016\/j.febslet.2006.03.088"},{"key":"2021120902021098000_R20","doi-asserted-by":"crossref","unstructured":"Kontaridis MI, Swanson KD, David FS, Barford D, Neel BG. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J Biol Chem.\u20082006;281:6785\u20136792","DOI":"10.1074\/jbc.M513068200"},{"key":"2021120902021098000_R21","doi-asserted-by":"crossref","unstructured":"Van der Hauwaert LG, Fryns JP, Dumoulin M, Logghe N. Cardiovascular malformations in Turner's and Noonan's syndrome. Br Heart J.\u20081978;40:500\u2013509","DOI":"10.1136\/hrt.40.5.500"},{"key":"2021120902021098000_R22","doi-asserted-by":"crossref","unstructured":"Burch M, Mann JM, Sharland M, Shinebourne EA, Patton MA, McKenna WJ. Myocardial disarray in Noonan syndrome. Br Heart J.\u20081992;68:586\u2013588","DOI":"10.1136\/hrt.68.12.586"},{"key":"2021120902021098000_R23","doi-asserted-by":"crossref","unstructured":"Burch M, Sharland M, Shinebourne E, Smith G, Patton M, McKenna W. Cardiologic abnormalities in Noonan syndrome: phenotypic diagnosis and echocardiographic assessment of 118 patients. J Am Coll Cardiol.\u20081993;22:1189\u20131192","DOI":"10.1016\/0735-1097(93)90436-5"},{"key":"2021120902021098000_R24","doi-asserted-by":"crossref","unstructured":"Digilio MC, Marino B, Toscano A, Giannotti A, Dallapiccola B. Atrioventricular canal defect without Down syndrome: a heterogeneous malformation. Am J Med Genet.\u20081999;85:140\u2013146","DOI":"10.1002\/(SICI)1096-8628(19990716)85:2<140::AID-AJMG8>3.0.CO;2-A"},{"key":"2021120902021098000_R25","doi-asserted-by":"crossref","unstructured":"Sharland M, Morgan M, Smith G, Burch M, Patton MA. Genetic counselling in Noonan syndrome. Am J Med Genet.\u20081993;45:437\u2013440","DOI":"10.1002\/ajmg.1320450407"},{"key":"2021120902021098000_R26","doi-asserted-by":"crossref","unstructured":"Araki T, Mohi MG, Ismat FA, et al. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med.\u20082004;10:849\u2013857","DOI":"10.1038\/nm1084"},{"key":"2021120902021098000_R27","doi-asserted-by":"crossref","unstructured":"Chen B, Bronson RT, Klaman LD, et al. Mice mutant for Egfr and Shp2 have defective cardiac semilunar valvulogenesis. Nat Genet.\u20082000;24:296\u2013299","DOI":"10.1038\/73528"},{"key":"2021120902021098000_R28","doi-asserted-by":"crossref","unstructured":"Rodriguez-Viciana P, Tetsu O, Tidyman WE, et al. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science.\u20082006;311:1287\u20131290","DOI":"10.1126\/science.1124642"},{"key":"2021120902021098000_R29","doi-asserted-by":"crossref","unstructured":"Chang CP, Neilson JR, Bayle JH, et al. A field of myocardial-endocardial NFAT signaling underlies heart valve morphogenesis. Cell.\u20082004;118:649\u2013663","DOI":"10.1016\/j.cell.2004.08.010"},{"key":"2021120902021098000_R30","doi-asserted-by":"crossref","unstructured":"Graef IA, Chen F, Crabtree GR. NFAT signaling in vertebrate development. Curr Opin Genet Dev.\u20082001;11:505\u2013512","DOI":"10.1016\/S0959-437X(00)00225-2"},{"key":"2021120902021098000_R31","doi-asserted-by":"crossref","unstructured":"Schulz RA, Yutzey KE. Calcineurin signaling and NFAT activation in cardiovascular and skeletal muscle development. Dev Biol.\u20082004;266:1\u201316","DOI":"10.1016\/j.ydbio.2003.10.008"},{"key":"2021120902021098000_R32","doi-asserted-by":"crossref","unstructured":"Wilkins BJ, Molkentin JD. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem Biophys Res Commun.\u20082004;322:1178\u20131191","DOI":"10.1016\/j.bbrc.2004.07.121"},{"key":"2021120902021098000_R33","doi-asserted-by":"crossref","unstructured":"Uhlen P, Burch PM, Zito CI, Estrada M, Ehrlich BE, Bennett AM. Gain-of-function\/Noonan syndrome SHP-2\/Ptpn11 mutants enhance calcium oscillations and impair NFAT signaling. Proc Natl Acad Sci USA.\u20082006;103:2160\u20132165","DOI":"10.1073\/pnas.0510876103"},{"key":"2021120902021098000_R34","doi-asserted-by":"crossref","unstructured":"Weismann CG, Hager A, Kaemmerer H, et al. PTPN11 mutations play a minor role in isolated congenital heart disease. Am J Med Genet A.\u20082005;136:146\u2013151","DOI":"10.1002\/ajmg.a.30789"},{"key":"2021120902021098000_R35","doi-asserted-by":"crossref","unstructured":"Roberts AE, Hult B, Rehm HL, et al. The PTPN11 gene is not implicated in nonsyndromic hypertrophic cardiomyopathy. Am J Med Genet A.\u20082005;132:333\u2013334","DOI":"10.1002\/ajmg.a.30405"},{"key":"2021120902021098000_R36","doi-asserted-by":"crossref","unstructured":"Bosi G, Scorrano M, Tosato G, Forini E, Chakrokh R. The Italian Multicentric Study on Epidemiology of Congenital Heart Disease: first step of the analysis. Working Party of the Italian Society of Pediatric Cardiology. Cardiol Young.\u20081999;9:291\u2013299","DOI":"10.1017\/S1047951100004960"},{"key":"2021120902021098000_R37","doi-asserted-by":"crossref","unstructured":"Stephensen SS, Sigfusson G, Eiriksson H, et al. Congenital cardiac malformations in Iceland from 1990 through 1999. Cardiol Young.\u20082004;14:396\u2013401","DOI":"10.1017\/S1047951104004081"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/119\/6\/e1325\/1119106\/zpe006070e1325.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/119\/6\/e1325\/1119106\/zpe006070e1325.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T03:52:50Z","timestamp":1639021970000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/119\/6\/e1325\/70624\/The-Spectrum-of-Cardiac-Anomalies-in-Noonan"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,1]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2007,6,1]]},"published-print":{"date-parts":[[2007,6,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2006-0211","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,1]]}}}